Evaluation of Chemotherapy Side Effects in Bladder Cancer Patients at Dr. Pirngadi Regional Hospital
Keywords:
Side effects, bladder cancer, chemotherapy.Abstract
Introduction: Bladder cancer is a pathological condition in which there is uncontrolled and abnormal proliferation or growth of cells that form the lining of the bladder wall. One of the current methods of treating bladder cancer is chemotherapy. Chemotherapy has a substantial effect in reducing the number of cancer cells because its mechanism of action aims to induce cell death and inhibit the proliferation of cancer cells. However, patients undergoing chemotherapy treatment often experience various symptoms that can originate from the side effects of chemotherapy itself. This study aims to evaluate the description of the side effects of chemotherapy drugs in bladder cancer patients at Dr. Pirngadi Regional Hospital. Methods: This study was conducted using a retrospective observational study design with a cross-sectional design. Sampling in this study used the Total Sampling technique. The samples obtained were 42 samples. Data collection was obtained through secondary data taken from medical records obtained from Dr. Pirngadi Regional Hospital, Medan City and analyzed using univariate tests. Results: The most commonly used chemotherapy drugs by bladder cancer patients were the combination of gemcitabine-cisplatin (64.3%) and epirubicin (35.7%) and the most common side effects were dyspepsia (34.5%), followed by joint pain (23.6%), allergic responses and swelling (12.7%), infection (5.5%), thrombocytopenia and constipation (3.6%), hypovolemic shock (1.8%), vertigo, and neutropenia (0.9%). Conclusion: The most commonly used chemotherapy drugs by bladder cancer patients at Dr. Pirngadi Regional Hospital were gemcitabine-cisplatin with the most common side effect being dyspepsia.
References
Halaseh SA, Halaseh S, Alali Y, Ashour ME, Alharayzah MJ. A review of the etiology and epidemiology of bladder cancer: All you need to know. Cureus. 2022;14(7). doi:10.7759/cureus.27330.
Susilawati S, Syabaniah RN, Riniawati R. Pengaruh asupan makanan dan stress terhadap kondisi kesehatan pasien kemoterapi. Jurnal Sains dan Kesehatan. 2021;3(3):470–477. doi:10.25026/jsk.v3i3.469.
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2022: An overview. International Journal of Cancer. 2024;149(4):778–789. doi:10.1002/ijc.33588.
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. International Journal of Cancer. 2024;149(4):778–789. doi:10.1002/ijc.33588.
Umbas R, Hardjowijoto S, Arif C, Safriadi F, Djatisoesanto W, Sihombing AT. Panduan Penanganan Kanker Kandung Kemih Tipe Urotelial. 2014.
Laksono BC, Wulansari IY. Akselerasi peningkatan kesehatan di Indonesia: Efektivitas kemoterapi kanker prostat dengan analisis. Seminar Nasional Official Statistics. 2019:347–356.
Parasian J, Susilowati Y, Maulidia Septimar Z, Haeriyah S. Hubungan efek samping kemoterapi dengan kualitas hidup pasien kanker payudara di Rumah Sakit Kanker Dharmais Provinsi DKI Jakarta tahun 2023. Jurnal Ilmiah Ilmu Kesehatan dan Kedokteran. 2024;2(1):115–126. doi:10.55606/termometer.v2i1.2808.
W MK. Relaksasi otot progresif terhadap status fungsional pasien kanker dengan kemoterapi: Literature review. 2019;(April):95–101.
Haryani S. Evaluasi penggunaan obat kemoterapi pada pasien kanker payudara di RSUP Fatmawati periode Februari 2021. Jurnal Farmasi Klinik Base Practice. 2022;1(1):50–60. doi:10.58815/jfklin.v1i1.19.
Arisanti JP, Saptarina N, Andarini YD. Evaluasi penggunaan obat kemoterapi pada penderita kanker payudara di RSUP Dr. Soeradji Tirtonegoro periode 2018. Pharmaceutical Journal of Islamic Pharmacy. 2020;4(2):1. doi:10.21111/pharmasipha.v4i2.4960.
Yang F, Liu G, Wei J, Dong Y, Zhang X, Zheng Y. Relationship between bladder cancer, nutritional supply, and treatment strategies: A comprehensive review. Nutrients. 2023;15(17):1–17. doi:10.3390/nu15173812.
Hendarso A, Radityo M. Kanker kandung kemih. 2024.
Anugrah PP, Nandana PI, Andari MY. Insidensi penyakit kanker buli-buli di RSUD Provinsi Nusa Tenggara Barat periode 2017–2018. Unram Medical Journal. 2019;8(2):1. doi:10.29303/jku.v8i2.332.
Shadab R, Nerli R, Bidi S, Ghagane S. Risk factors for bladder cancer: Results of a survey of hospital patients. Journal of Cancer & Allied Specialties. 2022;9(1):1–7. doi:10.37029/jcas.v9i1.485.
Whynot EG, Tomko AM, Dupré DJ. Anticancer properties of cannabidiol and Δ9-tetrahydrocannabinol and synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines. Journal of Cannabis Research. 2023;5(1). doi:10.1186/s42238-023-00174-z.
Perše M. Cisplatin mouse models: Treatment, toxicity and translatability. Biomedicines. 2021;9(10). doi:10.3390/biomedicines9101406.
Dahlgren D, Sjöblom M, Hellström PM, Lennernäs H. Chemotherapeutics-induced intestinal mucositis: Pathophysiology and potential treatment strategies. Frontiers in Pharmacology. 2021;12:1–12. doi:10.3389/fphar.2021.681417.
Yan H, Wang P, Yang F, et al. Anticancer therapy-induced adverse drug reactions in children and preventive and control measures. Frontiers in Pharmacology. 2024;15:1–14. doi:10.3389/fphar.2024.1329220.
Matesun DA, Mensah KB, Yamoah P, Bangalee V, Padayachee N. Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase. Journal of Oncology Pharmacy Practice. 2022. doi:10.1177/10781552221113578.
McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments. Frontiers in Pharmacology. 2016;7:1–14. doi:10.3389/fphar.2016.00414.
Amiri AH, Jaferian S. Post-chemotherapy arthralgia and arthritis in lung cancer. South Asian Journal of Cancer. 2012;1(2):72–75. doi:10.4103/2278-330X.103715.
Pribadi YS, Yuliastuti F, Santi Hapsari W. Literature review analysis of the side effects of chemotherapy in cervical cancer patients in Southeast Asia. Urecol Journal Part G: Multidisciplinary Research. 2022;2(2):93. doi:10.53017/ujmr.207.
Iskandar Z, Bakti S, Nyilo P. Penurunan hemoglobin, neutrofil, dan trombosit pascakemoterapi cisplatin-paclitaxel pada penderita tumor ganas kepala dan leher. Jurnal THT-KL. 2017;10(1):1–10.
Prayuenyong P, Taylor JA, Pearson SE, et al. Vestibulotoxicity associated with platinum-based chemotherapy in survivors of cancer: A scoping review. Frontiers in Oncology. 2018;8:363. doi:10.3389/fonc.2018.00363.
